BeOne Medicines (NasdaqGS:ONC) is back in focus after EHA 2026 data for BRUKINSA, tacabrutideg and the BRUKINSA plus sonrotoclax regimen in B-cell malignancies, highlighting long-term efficacy signals and detailed real-world evidence.

Despite the strong flow of clinical and index news, BeOne Medicines’ shares have eased, with the 30-day share price return down 9.82% and year-to-date share price return down 14.96%, while the 3-year total shareholder return remains up 32.10%.

If this kind of oncology pipeline has your attention, it can be useful to scan other cancer and biotech leaders using our healthcare AI stock ideas in the 40 healthcare AI stocks.

With BeOne Medicines’ shares down over the past year yet trading at a sizable gap to analyst targets and intrinsic estimates, is the market offering you a discounted entry into a broad oncology platform, or already pricing in future growth?

Most Popular Narrative: 35.7% Undervalued

BeOne Medicines' most followed narrative pegs fair value at $411.51 per share, well above the last close at $264.48, framing a sizable valuation gap for investors to weigh.

The company's robust pipeline, including multiple late-stage oncology assets (over 20 Phase III trials and >10 proof-of-concept readouts expected in the next 18 months), leverages internal R&D capabilities and the GlueXplorer™ platform to rapidly develop targeted, personalized medicines, which is well aligned with the shift toward precision therapeutics and supports the potential for long-term earnings and margin expansion as products commercialize.

Curious what kind of revenue path and margin profile has to sit behind that pipeline story? The narrative leans on brisk earnings expansion, richer profitability, and a premium profit multiple that still steps down from today.

Result: Fair Value of $411.51 (UNDERVALUED)

However, the story can change quickly if competition chips away at BRUKINSA’s heavy reliance, or if rising R&D and late stage trial setbacks pressure margins.

Another View: Price Tag Tells a Different Story

That narrative-based fair value of $411.51 sits uneasily beside today’s P/E of 57.3x. This is far richer than both the US Biotechs industry at 16.5x and peers at 31.2x, and also above a 32.4x fair ratio that the market could ultimately move toward.

If earnings do not line up with the most optimistic assumptions, this premium multiple could act as a buffer, or it could be a source of downside risk if sentiment cools.

Next Steps

The mix of optimism and caution in this story is clear, so move quickly to review the details and form your own view by checking the 4 key rewards.

Looking for more investment ideas?

If you want to sharpen your watchlist beyond BeOne Medicines, now is the time to scan targeted stock ideas that match clear financial and return goals.

• Hunt for mispriced opportunities by reviewing companies highlighted in the 44 high quality undervalued stocks to see which stocks the data flags as trading below their fundamentals.
• Strengthen your income stream by focusing on companies in the 8 dividend fortresses that pair higher yields with the potential for more consistent payouts.
• Target resilience by scanning the 71 resilient stocks with low risk scores and see which stocks stand out for sturdier risk profiles and steadier financials before others catch on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.